Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-01

Clinical Trial Update: Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cannabidiol for craving reduction and relapse prevention in opioid use disorder; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cannabidiol (cannabidiol)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Opioid-use Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-08-01